Genetic and Pharmacologic Inhibition of Mitochondrial-dependent Necrosis Atte uates Muscular Dystrophy | Debio 025 | / | Publications

Menu Content/Inhalt

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Genetic and Pharmacologic Inhibition of Mitochondrial-dependent Necrosis Atte uates Muscular Dystrophy

Millay DP, Sargent MA, Osinka H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J, Molkentin JD

Nature Medicine 2008 March 16